Shreeyashi Ojha is a journalist who writes for BioProcess International, covering topics related to the biopharmaceutical industry, including drug manufacturing, facility expansions, and acquisitions. Her work has also been featured in Asiana Times, where she has contributed articles on various subjects within the life sciences and healthcare sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Shreeyashi Ojha's focus is on healthcare and pharmaceuticals, particularly on industry developments such as mergers, acquisitions, investments, and expansions. She primarily covers press releases and private sector announcements related to pharmaceutical companies' activities and strategic moves.
When reaching out to Shreeyashi or pitching her a story, it would be beneficial to provide insights into the latest happenings within major pharmaceutical companies, biotechnology firms or CDMOs (Contract Development and Manufacturing Organizations). Additionally, experts with knowledge of gene therapy advancements could offer valuable input for her articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
In a bid to bolster pandemic preparedness, Sanofi has opened a modular vaccine manufacturing plant in Tuas Biomedical Park, Singapore.
Fostering a culture of compliance and quality alignment with Western regulators is vital for India's biomanufacturing growth: “If you are open for business every day, you have to be ready for inspection every day.”
Danish pharma giant Novo Nordisk will acquire Novavax’s manufacturing facility in the Czech Republic.
By: Shreeyashi Ojha
Biocon chief operations officer (COO) says that to reach its full potential, India must drop its “colonial mindset.”
By: Shreeyashi Ojha
Rare genetic-disease focused firm BioMarin Pharmaceutical has added a four-storied laboratory to its Cork, Ireland facility.
By: Shreeyashi Ojha
Amid the booming demand for diabetes and weight loss drugs, Sanofi and Novo Nordisk have expanded their facilities in China, and Denmark respectively.
By: Shreeyashi Ojha
CDMOs AGC Biologics and Resilience will kick off the new year with fresh CEOs, while bioprocess vendor Sartorius has named a successor to Joachim Kreuzburg. Pour yourself a festive drink and dive into BioProcess Insider's last recruitment roundup of 2024.
By: Shreeyashi Ojha
Asahi Kasei Pharma has licensed Chiome Bioscience’s humanized antibody anti-CX3CR1.
The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.
In addition to producing glucagon-like peptide-1 (GLP-1) drugs for an anonymous partner over five years, the Korean firm is consolidating its brands.
(833) 317-6278 
.jpg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
